Infigratinib

Unassigned

New Medicines

Inoperable/unresectable, late-stage metastatic bile duct cancer (cholangiocarcinoma) - first-line therapy

Information

New molecular entity
BridgeBio Pharma
BridgeBio Pharma

Development and Regulatory status

None
None
Phase III Clinical Trials
Yes

Category

Pan-fibroblast growth factor receptor (FGF-R) kinase 1-3 inhibitor.
Cholangiocarcinoma arises from the cells within the bile ducts. It is often diagnosed late (stages III and IV) and the prognosis is poor. It is most common in those over 70 years old and is more common in men than women [1]. Incidence is 1-2 per 100,000 population per year in the UK [2].
Inoperable/unresectable, late-stage metastatic bile duct cancer (cholangiocarcinoma) - first-line therapy
Oral

Invasive bladder (urothelial) cancer - post-surgery

Information

New molecular entity
BridgeBio Pharma
BridgeBio Pharma

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

FGFR1-3 selective tyrosine kinase inhibitor
The overall incidence of bladder cancer in the UK is 11.4 per 100,000 population, seventh most common cancer [2].
Invasive bladder (urothelial) cancer - post-surgery
Oral